Evidence map›Paper›PMID 42654145›Full record

ArticlePharmaceutics2026

Design, Synthesis and Biological Evaluation of Novel SN38 Based Albumin-Binding Peptide-Drug Conjugates in Pancreatic Ductal Adenocarcinoma.

Yi Su, Yingxin Lu, Jiahui Yu, Chen Jin, Yi Chen, Wei Lu, Jian Ding

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi SuSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Yingxin LuSchool of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China.
Jiahui YuSchool of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China.
Chen JinShanghai Tekanbio Pharm-Tech Co., Ltd., Room 4001, Floor 4, Unit 3, Building 8, No. 160, Basheng Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 200131, China.
Yi ChenState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Wei LuSchool of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China.
Jian DingSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.

Funding

Ministry of Science and Technology of the People's Republic of China 2025ZD1800503National Natural Science Foundation of China 22575089Shanghai Tekanbio Pharm-Tech Co., Ltd.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

albumin-bindingextra domain B fibronectinpancreatic ductal adenocarcinomaZD2 peptide

Identifiers

PMID42654145
PMCPMC13517058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.